Ingenia Therapeutics, a Clinical-Stage Biotechnology Company, Has Received Approval for an Initial Public Offering on the Korea Exchange (KRX)
Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that the company has received approval from the KRX to proceed with its Initial Public Offering (IPO). The move marks a pivotal transition for the company, supported by a robust pipeline that includes two clinical-stage assets, one of which is IGT-427 (now called MK-8748), an investigational bi-specific antibody (Anti-VEGF/TIE2), for patients with retinal diseases being developed by Merck (known as MSD outside of the US and Canada).
